Mi az ára Timber Pharmaceuticals, Inc. (TMBR)

Timber Pharmaceuticals, Inc. (TMBR) ára $0.0101

Mi a Timber Pharmaceuticals, Inc. (TMBR piaci tőkésítése)

Timber Pharmaceuticals, Inc. piaci tőkésítése (TMBR) $5.32K

Timber Pharmaceuticals, Inc. (TMBR) Ár és Piaci Kapitalizáció

Timber Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the research, development, and market introduction of treatments for rare dermatological conditions. The company's key product candidates include: TMB-001, a patented topical isotretinoin formulation, which has successfully completed Phase 2b clinical trials. It is designed to address moderate to severe forms of Congenital Ichthyosis (CI), a group of uncommon genetic disorders affecting skin keratinization. TMB-002, a proprietary topical rapamycin, currently undergoing Phase 2b clinical trials. This therapy targets facial angiofibroma associated with Tuberous Sclerosis Complex, a complex genetic disorder characterized by the growth of benign tumors in multiple organs. TMB-003, a unique Sitaxsentan formulation functioning as a selective endothelin-A receptor antagonist, which is in preclinical development for various sclerotic skin diseases. Additionally, through a licensing agreement with AFT Pharmaceuticals Limited, Timber Pharmaceuticals is advancing two topical minocycline therapies: BPX-01, now in Phase 3 development for treating inflammatory lesions of acne vulgaris. BPX-04, which is prepared for Phase 3 trials, targeting papulopustular rosacea. Founded in 2019, Timber Pharmaceuticals is headquartered in Basking Ridge, New Jersey.

A TMBR ára	B aktíva	A B piaci tőkésítése	Eredmények
$10,227,038 $5.32K	NVDA	$5.383T	+101,257,803,053.34%
$8,403,338 $5.32K	AAPL	$4.423T	+83,201,368,693.29%
$7,903,663 $5.32K	GOOG	$4.160T	+78,254,084,322.11%
$6,959,394 $5.32K	MSFT	$3.663T	+68,904,895,245.87%
$5,492,612 $5.32K	AMZN	$2.891T	+54,382,301,214.11%

A TMBR ára

B aktíva

A B piaci tőkésítése

Eredmények

$10,227,038 $5.32K